Quick answer
Teva Pharmaceutical Industries Limited (TEVA) reported revenue of $17.26B and net income of $1.41B for the fiscal year ended 2025-12-31, up 4.3% from $16.54B the year before, per its 10-K filed with the SEC on 2026-02-03.
Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2025 (FY ending 2025-12-31) | $17.26B | $1.41B | — |
| 2024 (FY ending 2024-12-31) | $16.54B | -$1.64B | — |
| 2023 (FY ending 2023-12-31) | $15.85B | -$559.0M | — |
| 2022 (FY ending 2022-12-31) | $14.93B | -$2.45B | — |
| 2021 (FY ending 2021-12-31) | $15.88B | $417.0M | — |
| 2020 (FY ending 2020-12-31) | $16.66B | -$3.99B | — |
| 2019 (FY ending 2019-12-31) | $16.89B | -$999.0M | — |
| 2018 (FY ending 2018-12-31) | $18.27B | -$2.15B | — |
| 2017 (FY ending 2017-12-31) | $21.85B | -$16.27B | — |
| 2016 (FY ending 2016-12-31) | $21.90B | $329.0M | — |
Frequently asked questions
What is Teva Pharmaceutical Industries Limited's annual revenue?
Teva Pharmaceutical Industries Limited (TEVA) reported revenue of $17.26B and net income of $1.41B for the fiscal year ended 2025-12-31, up 4.3% from $16.54B the year before, per its 10-K filed with the SEC on 2026-02-03.
What is TEVA's profit margin?
Teva Pharmaceutical Industries Limited's net margin was 8.2% in the fiscal year ended 2025-12-31.
Related
- TEL revenue, net income and debt history (Te Connectivity Plc)
- TEM revenue, net income and debt history (Tempus AI, Inc.)
- TER revenue, net income and debt history (Teradyne, Inc.)
- TGT revenue, net income and debt history (Target Corporation)
- TGTX revenue, net income and debt history (Tg Therapeutics, Inc.)
- THG revenue, net income and debt history (Hanover Insurance Group, Inc.)
- TJX revenue, net income and debt history (The TJX Companies, Inc.)
- TKO revenue, net income and debt history (Tko Group Holdings, Inc.)
Last updated Oct 17, 2026, 10:23 PM ET. Data only, not financial or tax advice.